MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2–Positive and/or Hormone Receptor–Negative Breast Cancers in the I-SPY 2 Trial

PURPOSE: The phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin is a key pathway of survival and therapeutic resistance in breast cancer. We evaluated the pan-Akt inhibitor MK-2206 in combination with standard therapy in patients with high-risk early-stage breast cancer. PATIENTS AND ME...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Oncol
Hlavní autoři: Chien, A. Jo, Tripathy, Debasish, Albain, Kathy S., Symmans, W. Fraser, Rugo, Hope S., Melisko, Michelle E., Wallace, Anne M., Schwab, Richard, Helsten, Teresa, Forero-Torres, Andres, Stringer-Reasor, Erica, Ellis, Erin D., Kaplan, Henry G., Nanda, Rita, Jaskowiak, Nora, Murthy, Rashmi, Godellas, Constantine, Boughey, Judy C., Elias, Anthony D., Haley, Barbara B., Kemmer, Kathleen, Isaacs, Claudine, Clark, Amy S., Lang, Julie E., Lu, Janice, Korde, Larissa, Edmiston, Kirsten K., Northfelt, Donald W., Viscusi, Rebecca K., Yee, Douglas, Perlmutter, Jane, Hylton, Nola M., van’t Veer, Laura J., DeMichele, Angela, Wilson, Amy, Peterson, Garry, Buxton, Meredith B., Paoloni, Melissa, Clennell, Julia, Berry, Scott, Matthews, Jeffrey B., Steeg, Katherine, Singhrao, Ruby, Hirst, Gillian L., Sanil, Ashish, Yau, Christina, Asare, Smita M., Berry, Donald A., Esserman, Laura J.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2020
Témata:
ORIGINAL REPORTS
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7106976/
https://ncbi.nlm.nih.gov/pubmed/32031889
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.01027
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky